Integrative Physiology |
From the Department of Pharmacology (M.I., A.D.M., K.Z., G.C.W.); and Department of Surgery (B.I.T., P.L.P., G.C.W.), Division of Neurological Surgery, University of Vermont College of Medicine, Burlington.
Correspondence to George C. Wellman, PhD, University of Vermont, Department of Pharmacology, Given Bldg, 89 Beaumont Ave, Burlington, VT 05405-0068. E-mail george.wellman{at}uvm.edu
| Abstract |
|---|
|
|
|---|
30% in myocytes isolated from rabbit cerebral arteries but did not directly alter the activity of voltage-dependent Ca2+ channels or large conductance Ca2+-activated (BK) channels. A combination of tyrosine kinase inhibitors (tyrphostin AG1478, tyrphostin A23, tyrphostin A25, genistein) abolished both oxyhb-induced suppression of Kv channel currents and oxyhb-induced constriction of isolated cerebral arteries. The Kv channel blocker 4-aminopyridine also inhibited oxyhb-induced cerebral artery constriction. The observed oxyhb-induced decrease in Kv channel activity could represent either channel block, or a decrease in Kv channel density on the plasma membrane. To explore whether oxyhb altered trafficking of Kv channels to the plasma membrane, we used an antibody generated against an extracellular epitope of Kv1.5 channels. In the presence of oxyhb, staining of Kv1.5 on the plasma membrane surface was markedly reduced. Furthermore, oxyhb caused a loss of spatial distinction between staining with Kv1.5 and the general anti-phosphotyrosine antibody PY-102. We propose that oxyhb-induced suppression of Kv currents occurs via a mechanism involving enhanced tyrosine kinase activity and channel endocytosis. This novel mechanism may contribute to oxyhb-induced cerebral artery constriction following SAH.
Key Words: voltage-dependent potassium channels vascular smooth muscle cerebral arteries subarachnoid hemorrhage oxyhemoglobin
| Introduction |
|---|
|
|
|---|
Activators of protein kinase C (PKC) can decrease Kv channel activity in vascular smooth muscle,10,11 and enhanced tyrosine kinase activity has been demonstrated to suppress the activity of Kv1 family members in other cell types.12,13 The exact mechanisms linking enhanced kinase activity to Kv channel suppression in cerebral arteries is unclear. However, a recent report has demonstrated that, in a model system, muscarinic receptor activation leads to Kv1.2 channel suppression by enhanced tyrosine kinase activity and channel internalization via endocytosis.14
Oxyhemoglobin (oxyhb) causes cerebral artery constriction and is among the blood components contributing to the pathogenesis of cerebral vasospasm following SAH.15,16 A number of cellular mechanisms have been reported to contribute to the vasoconstrictor actions of oxyhb and SAH, including increased PKC and tyrosine kinase activity.1620 The objective of the present study was to examine the acute impact of oxyhb on Kv currents in freshly isolated cerebral artery myocytes. Here we demonstrate that oxyhb leads to Kv channel suppression via a mechanism involving tyrosine kinase, but not PKC activity. Furthermore, we provide novel evidence indicating that oxyhb decreases staining of Kv1.5 channels on the cell surface, consistent with increased channel endocytosis. This mechanism of Kv channel suppression may contribute to oxyhb-induced cerebral artery constriction.
| Materials and Methods |
|---|
|
|
|---|
Measurements of Arterial Diameter
Cerebral artery segments were cannulated on glass pipettes mounted in a 5-mL myograph chamber (Living Systems Instruments, Burlington, Vt), as previously described.22,23 Arteries were discarded if an initial constriction representing less than a 50% decrease in diameter was observed when arteries were exposed to elevated extracellular K+ (60 mmol/L).
Measurements of Kv and VDCC Currents
Vascular smooth muscle cells were enzymatically isolated from cerebral arteries24 and the perforated-patch configuration of the patch-clamp technique was used to measure voltage-dependent K+ (Kv) currents.6 The external (bath) solution contained (in mmol/L): 135 NaCl, 5.4 KCl, 1.8 CaCl2, 10 HEPES, 1 MgCl2, 5.2 glucose (pH=7.4). Patch pipettes (3 to 5 M
) were filled with an internal solution that contained (in mmol/L): 110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 0.05 EGTA, 10 HEPES with 200 µmol/L amphotericin B (pH=7.2). Whole-cell VDCC currents were measured using the conventional whole-cell configuration of the patch-clamp technique.21 The external (bath) solution contained (in mmol/L): 125 NaCl, 10 BaCl2, 5 KCl, 10 HEPES, 1 MgCl2, 10 glucose (pH=7.4). Patch pipettes for VDCC measurements contained (in mmol/L): 130 CsCl, 10 ethylene glycol-bis(ß-aminoethyl ether)-N,N,N',N'-tetraacetic acid, 10 HEPES, 1 MgCl2, 2 ATP, 0.5 GTP, 5 phosphocreatine, 10 glucose (pH=7.2). Measurements were obtained from cells before, and following, 10 minutes of exposure to purified oxyhb A0 (provided by Hemosol Inc, Toronto, Canada).
Immunofluorescent Detection of Surface Kv1.5
Freshly dissociated cerebral artery myocytes were incubated at 37°C either in the presence or absence of oxyhb for 10 minutes then fixed with 4% formaldehyde. Cells were washed, then incubated with a rabbit polyclonal anti-Kv1.5 antibody (1:200 dilution) generated against an epitope in the second extracellular loop of the
subunit of the channel (a gift from Dr James Trimmer, University of California, Davis), and labeled with Alexa 568/goat anti-rabbit (Alexa 568-GAR) (1:500). This method produces staining of the channel on or near the cell surface and does not appear to stain intracellular channels. For cells costained with anti-phosphotyrosine antibody, surface Kv1.5 primary antibody was applied as described above; subsequently, cells were permeabilized with ice-cold acetone for 4 minutes, washed, blocked with PBS+3% goat serum for 20 minutes at 37°C, stained with the general anti-phosphotyrosine antibody PY-102 (1:200), and subsequently labeled with Alexa 568-GAR (1:500) and Alexa 647/goat anti-mouse (Alexa 647-GAM) (1:500). F-Actin was visualized using Alexa 488-phalloidin (1:200). Six to 10 cells were averaged from each animal (n).
Statistical Analysis
Data are presented as mean±SEM. Statistical significance was considered at the level of P<0.05 (*) or P<0.01 (**) using Students t test.
| Results |
|---|
|
|
|---|
|
VDCCs play an important role in the regulation of cerebral artery diameter and L-type calcium channel antagonists, such as diltiazem, are potent vasodilators of these arteries (Figure 1a and 1b). To examine whether oxyhb directly enhances VDCC activity, the whole-cell patch-clamp technique, with 10 mmol/L Ba2+ as the charge carrier, was used to measure VDCC currents in freshly isolated rabbit cerebral artery myocytes. From a holding potential of 80 mV, depolarizing voltage steps to +20 mV elicited inward membrane currents characteristic of VDCCs.21 Oxyhb (10 µmol/L or 100 µmol/L for 10 minutes) did not alter VDCC currents in cerebral artery myocytes isolated from healthy animals (Figure 1c and 1d). These data demonstrate that Ca2+ influx via VDCCs may be involved in oxyhb-induced cerebral artery constriction; however, oxyhb does not directly alter their open-state probability.
Oxyhb Decreases Kv Currents in Rabbit and Human Cerebral Artery Myocytes
As cerebral artery constriction requires Ca2+ entry through VDCCs, we next examined whether oxyhb indirectly increases VDCC activity via membrane potential depolarization through inhibition of K+ channels. Using the perforated patch-clamp technique, outward membrane K+ currents were elicited by a series of 10-mV depolarizing steps (to +50 mV) from a holding potential of 80 mV (Figure 2). Oxyhb (30 µmol/L) markedly decreased outward Kv currents in freshly isolated rabbit cerebral artery myocytes (Figure 2a and 2c). At +40 mV, oxyhb decreased outward K+ channel current density by approximately 40%. Although oxyhb reduced Kv currents, the activation time constants for these currents were similar in the absence (+40 mV,
=56.4±6.8 ms; n=11) and presence of oxyhb (+40 mV,
=54.2±5.0 ms; n=11).
|
Few studies have examined K+ channel function in the human cerebral vasculature. We therefore also examined the ability of oxyhb to influence Kv currents in small-diameter human cerebral arteries obtained from a consenting surgical patient. At +40 mV, the K+ channel current density was 16.5±6.9 pA/pF (n=3 cells from 1 individual), compared with the current density of 27.9±3.4 pA/pF observed in rabbit cerebral myocytes using similar recording conditions. Oxyhb reduced currents in human cerebral artery myocytes by approximately 40% (Figure 2b and 2d), a decrease similar to that observed in the rabbit.
Oxyhb Decreases Kv, but Not BK, Currents in Rabbit Cerebral Artery Myocytes
In cerebral artery myocytes, K+ currents evoked by membrane depolarization reflect the combined activity of large-conductance Ca2+-activated (BK) channels and delayed rectifier (Kv) channels. A hallmark of Kv channels is their block by 4-aminopyridine (4-AP).1 4-AP (10 mmol/L) reduced outward K+ currents in rabbit cerebral artery myocytes by 35% to 45% at membrane potentials between +10 and +50 mV (Figure 3). Following inhibition of Kv currents by 4-AP, oxyhb no longer reduced outward K+ currents (Figure 3a, 3b, and 3e), consistent with a suppression of Kv currents by oxyhb. For example, at +40 mV, K+ channel current density was reduced from 24.0±2.8 to 15.4±1.9 pA/pF by 4-AP, with no further reduction by oxyhb (13.9±0.8 pA/pF in the presence of 4-AP and oxyhb). Additionally, we used iberiotoxin (IBTX) (100 nmol/L), a selective blocker of BK channels, to examine whether oxyhb could also alter voltage-dependent BK channel activity. Consistent with a contribution of BK channels to outward K+ currents, IBTX decreased whole-cell K+ currents by approximately 40% at +40 mV. However, oxyhb still reduced outward K+ channel current density in the presence of IBTX (Figure 3c, 3d, and 3f). Furthermore, IBTX-sensitive BK current density at +40 mV was not significantly different in the absence (11.3±1.3 pA/pF) and presence (9.0±0.4 pA/pF) of oxyhb. These data demonstrate that oxyhb decreases the amplitude of Kv, but not BK, currents evoked by membrane potential depolarization in cerebral artery myocytes isolated from healthy rabbits. Functional studies examining diameter changes in isolated pressurized cerebral arteries were in accord with the actions of 4-AP and IBTX on K+ channel current densities (Figure 3e). Both IBTX and 4-AP constricted pressurized cerebral arteries, demonstrating the functional presence of BK and Kv channels. Consistent with our electrophysiological data, inhibition of Kv channels with 4-AP abolished oxyhb-induced cerebral artery constriction. However, oxyhb-induced constriction was still observed following inhibition of BK channels with IBTX. These data are consistent with oxyhb-induced Kv channel inhibition leading to cerebral artery constriction. In the presence of 4-AP, increasing extracellular K+ to 60 mmol/L caused an additional constriction (76±2% decrease in diameter; n=5), ensuring that 4-AP was not causing a maximal constriction in this tissue.
|
Oxyhb-Induced Suppression of Kv Currents: Involvement of Tyrosine Kinase Activity
We next sought to explore potential cell signaling pathways linking oxyhb to decreased Kv channel current density in freshly isolated cerebral artery myocytes. Activation of protein tyrosine kinases (PTKs) leads to suppression of Kv currents in nonvascular cultured cells.1214 To examine the involvement of PTKs in oxyhb-induced suppression of Kv currents in cerebral artery myocytes, we used a combination of PTK inhibitors including tyrphostin AG1478 (2.5 µmol/L), tyrphostin A23 (2.5 µmol/L), tyrphostin A25 (2.5 µmol/L), and genistein (15 µmol/L). This combination of PTK inhibitors abolished oxyhb-induced Kv current suppression (Figure 4a and 4b). Furthermore, PTK inhibitors abolished oxyhb-induced constriction of isolated pressurized cerebral arteries, whereas K+-induced constriction was unaltered (Figure 4c).
|
Previous work by others has demonstrated that PKC can reduce Kv channel activity in vascular smooth muscle10,11 and enhanced activity of several PKC isoforms, including PKC
, -
, and -
, can occur during oxyhb exposure or following SAH.16,20 However, we found that chelerythrine (1 µmol/L), an inhibitor of PKC isoforms
, ß1, ß2,
, and
and GF109203X (1 µmol/L), an inhibitor of PKC isoforms
,
, and
, did not impact the ability of oxyhb to suppress K+ currents (Figure 4d). However, both chelerythrine and GF109203X were effective in blunting Kv current suppression caused by the PKC activator 1,2-dioctanoyl-sn-glycerol (DOG) (1 µmol/L) (M. Koide and G.C.W., unpublished observations, 2006). These data suggest activity of PTKs, but not PKC, is involved in the inhibition of Kv channels by oxyhb in cerebral myocytes.
Oxyhb-Induced Decreased Surface Kv1.5 Channel Staining Involves Tyrosine Kinase Activity
Oxyhb-induced PTK activity could suppress Kv currents through a reduction in channel open probability or through a decrease in channel number on the plasma membrane. The kinetic properties of the 4-AP and oxyhb-sensitive K+ currents seemed similar, suggesting that channel number may be reduced. Kv1.5 is expressed in cerebral arteries25,26 and has been shown to undergo PTK-dependent phosphorylation in other cell types.27 In the absence of oxyhb, application of an antibody directed against an extracellular epitope of Kv1.5 to formaldehyde-fixed myocytes revealed staining for surface Kv1.5 within large but defined regions on the cell surface (Figure 5). Costaining of control cells with an anti-phosphotyrosine antibody (PY102) revealed phosphotyrosine rich vesicular compartments adjacent to the plasma membrane (see Figure 5, z-projection; and the online movie supplement, available at http://circres.ahajournals.org). Oxyhb elicited a redistribution of Kv1.5 into smaller, sharply defined foci (Figure 5). Reconstruction of a z-axis micrograph series suggests fusion of the phosphotyrosine-enriched vesicles with the surface Kv1.5 density (see Figure 5, z-projection; and online movie supplement). The above observations are consistent with oxyhb causing enhanced tyrosine kinase activity and tyrosine phosphorylation of Kv1.5, or a closely associated protein. In an attempt to strengthen these findings, efforts were made using Western blot to detect oxyhb-induced tyrosine phosphorylation of Kv1.5. However, using a variety of available antibodies generated against Kv1.5, or anti-phosphotyrosine residues, we were unable to immunoprecipitate sufficient quantities of the desired substrate to allow western blot detection of the phosphorylated protein. A number of factors, including inefficient detection of the specific rabbit epitope with available antibodies, comparatively low levels of Kv1.5 expression combined with a relatively small amount of total phosphorylated protein obtained from these 100 to 200 µm diameter cerebral arteries, or loss of phosphorylation by an associated phosphatase, may have contributed to our lack of success with this experimental series.
|
Using immunofluorescence, we did observe that oxyhb caused a significant reduction in the total amount of Kv1.5 detectable on the cell surface (Figure 6a), suggesting that oxyhb may elicit trafficking of Kv1.5 from the cell surface. Oxyhb did not change total F-actin staining, but did slightly reduce the average pixel area occupied by each cell, consistent with oxyhb-induced cell contraction. The oxyhb-induced decrease in surface staining of Kv1.5 was abolished by a combination of PTK inhibitors (Figure 6b). Collectively, these findings are consistent with the hypothesis that Kv1.5 suppression involves tyrosine phosphorylation-dependent trafficking of the channel from the cell surface.
|
Oxyhb Does Not Suppress Kv Channel Activity in Cerebral Artery Myocytes Following SAH
Oxyhb is among the blood components contributing to SAH-induced cerebral vasospasm,15,16,28 and previous work by others suggests altered Kv function following SAH.4,9 We next examined the ability of oxyhb to suppress Kv channel activity and constrict small-diameter cerebral arteries following experimental SAH. If oxyhb-induced Kv suppression occurs during SAH, we would predict that exogenous oxyhb would have little additional effect on arteries from SAH animals. Cerebral arteries were obtained from a rabbit SAH model 5 days after the intracisternal injection of whole blood. In the absence of exogenous oxyhb, K+ current density from SAH animals was reduced by approximately 30% compared with that of myocytes from control animals (Figure 7). Thus, the K+ channel current density in myocytes from SAH animals was similar to myocytes from healthy animals following acute exposure to oxyhb. Acute application of oxyhb failed to further suppress Kv currents in myocytes from SAH animals (Figure 7a and 7b). Based on the inability of oxyhb to suppress Kv currents following SAH, we hypothesized that oxyhb-induced constriction would be impaired in cerebral arteries from SAH animals. Consistent with this hypothesis, oxyhb did not constrict cerebral arteries from SAH animals in vitro (Figure 7c and 7d). As we have reported previously,21 in the absence of exogenous oxyhb, arteries from SAH animals exhibit enhanced pressure-induced constrictions that are abolished by the combination of an L-type VDCC blocker, diltiazem, and an R-type VDCC blocker, SNX-482. These findings suggest that oxyhb-induced Kv channel suppression may contribute to the complex series of events leading to enhanced cerebral artery constriction following SAH.
|
| Discussion |
|---|
|
|
|---|
Recent studies have revealed that in vascular myocytes, functional Kv channels likely represent heterotetramers of 2 Kv family members, Kv1.2 and Kv1.5.26,29,30 In arterial myocytes, mRNA levels of Kv1.5 are the most abundant of known Kv family members.25,31 Using an antibody generated against an extracellular epitope of Kv1.5, we observed that oxyhb caused a marked decrease in Kv1.5 staining on the surface of nonpermeabilized cells. A recent study by Choi et al32found that disruption of the endocytotic machinery leads to increased Kv1.5 currents and a corresponding increase in surface expression of this channel, whereas Nesti et al14 have found tyrosine kinase activity promoted suppression of Kv1.2 current via increased channel endocytosis. Thus, although our present study does not directly demonstrate oxyhb enhances Kv1.5 channel endocytosis, our observations are consistent with recent reports demonstrating that endocytotic activity can regulate Kv currents on the plasma membrane.
In the present study, we also provide 2 lines of evidence that enhanced tyrosine kinase activity is involved in oxyhb-induced suppression of Kv currents. Firstly, pharmacological inhibition of tyrosine kinases blocked the ability of oxyhb to suppress Kv current density (Figure 4) and abolished both oxyhb-induced decreased surface Kv1.5 staining (Figure 6) and cerebral artery constriction (Figure 4). Secondly, staining with a general anti-phosphotyrosine antibody revealed that oxyhb caused colocalization of phosphotyrosine and Kv1.5 signals (Figure 5). Although the identity of the specific tyrosine kinase linked to oxyhb-induced suppression of Kv1.5 remains to be determined, other investigators have demonstrated that Src kinase can bind to and phosphorylate Kv1.5.27 It is also possible that oxyhb could increase the activity of receptor-mediated tyrosine kinases such as the EGF receptor, which has been implicated in the suppression of Kv1.2 membrane currents.33 Although it is likely that Kv1.5 is a direct target for tyrosine phosphorylation, it is conceivable that phosphorylation of other Kv1 subunits within the channel or a closely associated protein may also play a role in the loss of surface channel.
The present work also suggests that oxyhb-induced suppression of Kv channels may contribute to the vascular pathology of cerebral vasospasm following aneurysm rupture and SAH. We found Kv currents were decreased in myocytes obtained from a rabbit SAH model and that the effects of SAH and acute exposure of oxyhb were not additive. Our data are consistent with previous reports suggesting Kv channel activity is decreased following SAH4,34 and provides the first evidence implicating oxyhb in this phenomenon. Alternatively, it is possible that the suppression of K+ currents following SAH represent a decrease in K+ channel expression, or altered expression of a signaling protein involved in the action of oxyhb on Kv channels. Additional studies are required to firmly establish the mechanism of decreased K+ channel activity following SAH.
In summary, this work demonstrates that oxyhb-induced suppression of Kv currents in cerebral artery myocytes occurs via tyrosine kinase-dependent reduction of Kv1.5 channels on the plasma membrane. This novel mechanism contributing to cerebral artery constriction may represent a more widespread mechanism whereby endogenous vasoactive substances modulate cerebral artery function. Furthermore, oxyhb-induced suppression of Kv currents may contribute to decreased cerebral blood flow and the accompanying neurological deficits associated with SAH.
| Acknowledgments |
|---|
Sources of Funding
This work was supported by the Totman Medical Research Trust Fund, the Peter Martin Brain Aneurysm Endowment, the American Heart Association (Scientist Development Grant 003029N), and the NIH (National Center for Research Resources grant P20 RR16435; National Heart, Lung, and Blood Institute grant R01 HL078983; and National Institute of Neurological Disorders and Stroke grant R01 NS050623).
Disclosures
None.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. E. Link, K. Murakami, M. Beem-Miller, B. I. Tranmer, and G. C. Wellman Oxyhemoglobin-Induced Expression of R-Type Ca2+ Channels in Cerebral Arteries Stroke, July 1, 2008; 39(7): 2122 - 2128. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koide, P. L. Penar, B. I. Tranmer, and G. C. Wellman Heparin-binding EGF-like growth factor mediates oxyhemoglobin-induced suppression of voltage-dependent potassium channels in rabbit cerebral artery myocytes Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1750 - H1759. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |